Halozyme Therapeutics Stock Price

-0.525 (-1.22%)
Upgrade to Real-Time
Regular Market


52 Week Range


Best deals to access real time data!
Ultimate Trader (Monthly)
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
Big Cap Pro
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Halozyme Therapeutics Incorporated HALO NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.525 -1.22% 42.365 13:05:41
Open Price Low Price High Price Close Price Prev Close
42.92 41.97 43.08 42.89
Bid Price Ask Price Spread News
42.35 42.38 0.03 - -
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
2,560 152,532 $ 42.44 $ 6,473,936 - 25.17 - 56.40
Last Trade Time Type Quantity Stock Price Currency
13:05:41 200 $ 42.365 USD


Draw Mode:

Halozyme Therapeutics Incorporated Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 6.03B 142.39M 122.53M $ 267.59M $ 134.14M 0.91 37.60
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - -156.37k 7.90%

more financials information »

Halozyme Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical HALO Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week39.953443.54539.953442.14796,8102.416.04%
1 Month45.4346.6239.953443.94635,299-3.07-6.75%
3 Months50.4350.7238.6543.06913,122-8.07-15.99%
6 Months48.28556.4038.6545.071,143,049-5.92-12.26%
1 Year27.3256.4025.1739.421,303,25115.0555.07%
3 Years17.3456.4012.7126.401,164,39125.03144.32%
5 Years9.2656.408.1821.551,190,58233.11357.51%

Halozyme Therapeutics Description

Halozyme Therapeutics is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme utilizes a strategy that focuses on developing its own proprietary products in therapeutic areas with significant unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.

Your Recent History
Halozyme T..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.